SUCLG2 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1
Alternative names
EC 6.2.1.4, G BETA, GTP specific succinyl-CoA synthetase beta subunit, GTP-specific succinyl-CoA synthetase subunit beta, SCS-betaG, SUCB2_HUMAN, Succinate CoA ligase GDP forming beta subunit, Succinate-Coenzyme A ligase, GDP-forming, beta subunit, Succinyl CoA ligase GDP forming beta chain mitochondrial, Succinyl-CoA ligase [GDP-forming] subunit beta, Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial, Succinyl-CoA synthetase beta-G chain, mitochondrial
Recommended products
SUCLG2 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1
- Concentration
Properties
- Gene name
- SUCLG2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The SUCLG2 protein also known as succinyl-CoA synthetase GDP-forming beta subunit is an essential component of cellular energy metabolism. It has an approximate molecular mass of 50 kDa. SUCLG2 is primarily expressed in various tissues including liver kidney and heart. It forms part of the succinyl-CoA synthetase enzyme complex which plays a role in the conversion of succinyl-CoA to succinate in the mitochondrial matrix.
- Biological function summary
SUCLG2 contributes to the production of GTP through substrate-level phosphorylation an important step in the tricarboxylic acid (TCA) cycle. As part of the succinyl-CoA synthetase complex it aids in the intricate process of energy conversion within mitochondria. The enzymatic activity of SUCLG2 ensures the proper balance of GTP within cells influencing various metabolic processes essential for cellular function and maintenance.
- Pathways
SUCLG2 operates within the TCA cycle and is a pivotal link in cellular respiration. In this pathway it ensures the conversion of carbon and energy flow important for energy production. SUCLG2's role here is closely related to the protein SUCLG1 with which it forms the functional succinyl-CoA synthetase complex. Additionally SUCLG2 participates in metabolic pathways related to the biosynthesis of amino acids further extending its influence on cellular metabolism.
- Associated diseases and disorders
SUCLG2 mutations have been implicated in mitochondrial diseases particularly those affecting energy metabolism. For instance patients with such mutations might experience metabolic myopathy syndromes. SUCLG2 also displays connections with SUCLG1 in these disorders given their role in the same enzymatic complex. Recognition of these associations helps in understanding the molecular basis of certain metabolic syndromes and potential avenues for therapeutic intervention.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human SUCLG2 knockout HEK-293T cell line (ab266677)
Allele-2: Insertion of the selection cassette in exon 1.
Sanger Sequencing - Human SUCLG2 knockout HEK-293T cell line (ab266677)
Allele-1: 1 bp insertion in exon1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com